These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 23922134)

  • 1. Management of OAB in those over age 65.
    Natalin R; Lorenzetti F; Dambros M
    Curr Urol Rep; 2013 Oct; 14(5):379-85. PubMed ID: 23922134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overactive bladder in the elderly: a guide to pharmacological management.
    Staskin DR
    Drugs Aging; 2005; 22(12):1013-28. PubMed ID: 16363885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The challenge of overactive bladder therapy: alternative to antimuscarinic agents.
    Lazzeri M; Spinelli M
    Int Braz J Urol; 2006; 32(6):620-30. PubMed ID: 17201939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
    Rai BP; Cody JD; Alhasso A; Stewart L
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].
    Rechberger T; Kulik-Rechberger B; Miotła P; Wróbel A
    Ginekol Pol; 2014 Mar; 85(3):214-9. PubMed ID: 24783434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic management of overactive bladder.
    Lam S; Hilas O
    Clin Interv Aging; 2007; 2(3):337-45. PubMed ID: 18044184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overactive bladder treatments in early phase clinical trials.
    Colli E; Digesu GA; Olivieri L
    Expert Opin Investig Drugs; 2007 Jul; 16(7):999-1007. PubMed ID: 17594185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.
    Hashim H; Abrams P
    Drugs; 2004; 64(15):1643-56. PubMed ID: 15257626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on Overactive Bladder Therapeutic Options.
    Babin CP; Catalano NT; Yancey DM; Pearl NZ; Koonce EM; Ahmadzadeh S; Shekoohi S; Cornett EM; Kaye AD
    Am J Ther; 2024 Jul-Aug 01; 31(4):e410-e419. PubMed ID: 37171410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New evidence in the treatment of overactive bladder.
    Brown ET; Martin L; Dmochowski RR
    Curr Opin Obstet Gynecol; 2015 Oct; 27(5):366-72. PubMed ID: 26308197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder.
    Araklitis G; Robinson D; Cardozo L
    Clin Interv Aging; 2020; 15():1493-1503. PubMed ID: 32921995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
    Swift SE; Siami P; Forero-Schwanhaeuser S
    Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overactive bladder: diagnosis and management.
    Robinson D; Cardozo L
    Maturitas; 2012 Feb; 71(2):188-93. PubMed ID: 22197347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trospium chloride treatment of overactive bladder.
    Biastre K; Burnakis T
    Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg.
    Brunton S; Kuritzky L
    Curr Med Res Opin; 2005 Jan; 21(1):71-80. PubMed ID: 15881477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.